Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος:	Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study.
Συγγραφείς:	Sorbye H; Cancer Clinic, Haukeland University Hospital, Bergen, Norway. halfdan.sorbye@helse-bergen.no.; Department of Clinical Science, University of Bergen, Bergen, Norway. halfdan.sorbye@helse-bergen.no., Hjortland GO; Department of Oncology, Oslo University Hospital, Oslo, Norway., Vestermark LW; Department of Oncology, University Hospital of Southern Denmark, Esbjerg, Denmark., Ladekarl M; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.; Department of Oncology, Clinical Cancer Research Center, Aalborg University Hospital, and Department of Clinical Medicine, Aalborg University, Aalborg, Denmark., Svensson J; Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden., Sundlöv A; Department of Oncology, Skåne University Hospital, Lund, Sweden., Janson ET; Department of Medical Sciences, Section of Endocrine Oncology, Uppsala University, Uppsala, Sweden., Garresori H; Department of Oncology, Stavanger University Hospital, Stavanger, Norway., Hofsli E; Department of Oncology, St.Olavs Hospital, Trondheim, Norway., Kersten C; Department of Research, Hospital of Southern Norway, Kristiansand, Norway., Elvebakken H; Department of Oncology, Ålesund Hospital, Møre og Romsdal Hospital Trust, Ålesund, Norway., Pfeiffer P; Department of Oncology, Odense University Hospital, Odense, Denmark., Morken S; Cancer Clinic, Haukeland University Hospital, Bergen, Norway.; Department of Clinical Science, University of Bergen, Bergen, Norway., Assmus J; Centre for Clinical Research, Haukeland University Hospital, Bergen, Norway., Lothe IMB; Department of Pathology, Oslo University Hospital, Oslo, Norway., Tabaksblat E; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark., Knigge U; Department of Surgery C and Endocrinology PE, Rigshospitalet, Faculty of Health Science, University of Copenhagen, Copenhagen, Denmark., Couvelard A; Department of Pathology, Bichat Hospital, Paris, France., Perren A; Institute of Tissue Medicine and Pathology, University of Bern, Bern, Switzerland., Langer SW; Department of Oncology, Rigshospitalet, Copenhagen, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
Πηγή:	British journal of cancer [Br J Cancer] 2025 Aug; Vol. 133 (3), pp. 316-324. Date of Electronic Publication: 2025 May 17.
Τύπος έκδοσης:	Journal Article; Multicenter Study
Γλώσσα:	English
Στοιχεία περιοδικού:	Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE
Imprint Name(s):	Publication: 2002- : London : Nature Publishing Group on behalf of Cancer Research UK Original Publication: London, Lewis.
Ιατρικοί όροι (MeSH):	Neuroendocrine Tumors/pathology , Neuroendocrine Tumors/drug therapy , Neuroendocrine Tumors/mortality , Digestive System Neoplasms/pathology , Digestive System Neoplasms/drug therapy , Digestive System Neoplasms/mortality, Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Humans ; Male ; Female ; Middle Aged ; Aged ; Prospective Studies ; Adult ; Prognosis ; Aged, 80 and over ; Treatment Outcome ; Neoplasm Grading
Περίληψη:	Background: Digestive high-grade neuroendocrine neoplasms (HG-NEN) are rare and classified as neuroendocrine carcinomas (NEC) or neuroendocrine tumours G3 (NET G3), and differ in clinical and molecular characteristics, response to treatment and prognosis. Methods: Prospective multicenter study registering clinical data on patients with digestive HG-NEN. Treatment outcome in patients with advanced disease was compared after centralized pathological re-evaluation. Results: 427 NEC and 117 NET G3 received palliative chemotherapy. Immediate progression rate was 41% and 24%, progression-free survival (PFS) 3.4 m and 7.4 m, overall survival (OS) 7.4 m and 21.8 m for NEC and NET G3, respectively. Significant factors for OS in NEC were performance status (PS), Ki-67 > 55%, alkaline phosphatase (ALP), age, sex and for PFS colorectal primary and PS. NEC Ki-67 < 55% had similar OS comparing treatment. Significant factors for OS in NET G3 were platinum-based treatment, PS, age and ALP, and for PFS platinum-based treatment. Conclusions: Survival was shorter than expected in this unique population-based cohort of advanced digestive HG-NEN, likely due to inclusion of elderly and patients with poor PS. Several novel prognostic factors were identified for NEC and NET G3. An initial sub-effective platinum-based treatment for NET G3 could not be compensated by later-line treatment. (© 2025. The Author(s).)
Competing Interests:	Competing interests: ML achieved an unrestricted grant from Scandion Oncology, Denmark. All other authors have declared no conflicts of interest. Ethics approval and consent to participate: The study was conducted according to the Declaration of Helsinki and approved by ethics committees in Norway (REK-vest-2012/940), Sweden (REC-Uppsala-Dnr-2012/285) and Denmark (Region-Hovedstaden-H-4-2012-108). All patients signed written informed consent.
Σχόλια:	Erratum in: Br J Cancer. 2025 Aug;133(3):420. doi: 10.1038/s41416-025-03095-1.. (PMID: 40659859)
References:	Neuroendocrinology. 2021;111(9):883-894. (PMID: 33002892) Sci Rep. 2017 Jan 11;7:40609. (PMID: 28074897) Clin Cancer Res. 2008 Dec 1;14(23):7798-803. (PMID: 19047107) Endocr Relat Cancer. 2023 Jul 11;30(8):. (PMID: 37184955) JCO Precis Oncol. 2023 Feb;7:e2200336. (PMID: 36753687) Cancer. 2020 May 1;126 Suppl 9:2086-2092. (PMID: 32293725) Endocr Relat Cancer. 2015 Aug;22(4):657-64. (PMID: 26113608) Cancers (Basel). 2022 Dec 31;15(1):. (PMID: 36612291) Endocr Relat Cancer. 2023 Feb 14;30(3):. (PMID: 36629395) Cancers (Basel). 2024 Jun 28;16(13):. (PMID: 39001438) Histopathology. 2020 Jan;76(2):182-188. (PMID: 31433515) Cancer Sci. 2014 Sep;105(9):1176-81. (PMID: 24975505) J Neuroendocrinol. 2023 Apr;35(4):e13256. (PMID: 37017614) Nat Commun. 2024 Aug 8;15(1):6753. (PMID: 39117670) J Neuroendocrinol. 2025 Mar;37(3):e13443. (PMID: 39243213) Lancet. 2024 Jun 29;403(10446):2807-2817. (PMID: 38851203) JAMA Oncol. 2022 Oct 1;8(10):1447-1455. (PMID: 35980649) Neuroendocrinology. 2019;108(1):54-62. (PMID: 30153658) Ann Oncol. 2013 Jan;24(1):152-60. (PMID: 22967994) Neuroendocrinology. 2017;104(1):85-93. (PMID: 26943788) Br J Cancer. 2024 Sep;131(4):676-684. (PMID: 38909137) Eur J Cancer. 2017 Jul;79:158-165. (PMID: 28501762) Ther Adv Med Oncol. 2023 Mar 16;15:17588359231156218. (PMID: 36950274) J Natl Compr Canc Netw. 2024 May 14;22(5):. (PMID: 38744314) Br J Cancer. 2023 Dec;129(12):1930-1939. (PMID: 37872405) Endocrine. 2021 Apr;72(1):268-278. (PMID: 32700133) Endocr Relat Cancer. 2021 Nov 11;29(1):1-14. (PMID: 34647903) Neuroendocrinology. 2023;113(4):457-469. (PMID: 36417840) Cancer. 2018 Feb 15;124(4):807-815. (PMID: 29211313) Endocr Relat Cancer. 2023 Aug 23;30(10):. (PMID: 37410378) Int J Cancer. 2018 Mar 15;142(6):1139-1147. (PMID: 29082524) Pancreas. 2021 May-Jun 01;50(5):727-731. (PMID: 34016894) Cancers (Basel). 2021 Apr 16;13(8):. (PMID: 33923759) Oncologist. 2021 May;26(5):383-388. (PMID: 33496040) J Natl Cancer Inst. 2017 Jan 27;109(5):. (PMID: 28130474) Mod Pathol. 2023 Mar;36(3):100065. (PMID: 36788102) Endocr Relat Cancer. 2021 Jun 23;28(8):549-561. (PMID: 34061764) J Neuroendocrinol. 2023 Mar;35(3):e13249. (PMID: 36924180) Oncologist. 2021 Nov;26(11):950-955. (PMID: 34342086)
Entry Date(s):	Date Created: 20250517 Date Completed: 20250805 Latest Revision: 20250807
Update Code:	20260130
PubMed Central ID:	PMC12322073
DOI:	10.1038/s41416-025-03054-w
PMID:	40382522
Βάση Δεδομένων:	MEDLINE

Full Text Finder

Περιγραφή
ISSN:	1532-1827
DOI:	10.1038/s41416-025-03054-w